#105 The new anti-platelet ticagrelor: Is it better than the old “new” clopidogrel?
CLINICAL QUESTION
How does the newer anti-platelet drug ticagrelor (Brillinta®) compare to clopidogrel for post-acute coronary syndrome (ACS)?
BOTTOM LINE
After ACS, ticagrelor reduces combined cardiovascular death, stroke, and myocardial infarction (MI) about 2% more than clopidogrel. Ticagrelor increases a few adverse events, particularly 6% more dyspnea, and effectiveness remains uncertain in North America.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
PLATO, multinational Randomized Controlled Trial (RCT) of 18,624 patients hospitalized for ACS +/- ST elevation, comparing ticagrelor vs. clopidogrel (both with usual care including ASA) for 12 months maximum,1,2 found statistically significant reduction in:
- Primary endpoint (composite of cardiovascular death, MI, or stroke), Number Needed to Treat (NNT) 53.
- Other outcomes better:
- Recurrent MI: NNT 91.
- Death from vascular causes: NNT 91.
- Death from any cause: NNT 71.
- No significant difference in stroke.
- Adverse reactions:
- No significant difference in any bleeding except:
- Bleeding worse when coronary artery bypass patients excluded, Number Needed to Harm (NNH) 143.
- Worse fatal intracranial hemorrhage, NNH 926.
- Any dyspnea, NNH 17; Requiring discontinuation, NNH 125.
- Non-fatal arrhythmias (ventricular pauses) were significantly increased with ticagrelor as well.3
- No significant difference in any bleeding except:
- Subgroup analysis of 1,800 patients in PLATO from North America showed much less favourable results: mortality was actually lower in clopidogrel group at 12 months.2,3
- Ticagrelor has several theoretical benefits over clopidogrel: it is a reversible platelet inhibitor, hepatic metabolism not required for activation (less intra-individual variability in response), and faster onset/offset of action.3,4
- Benefits of ticagrelor seem maintained in higher risk groups like those with renal insufficiency5 and diabetes.6
- Ticagrelor proposed as an alternative in clopidogrel non-responders.7
- Unanswered concerns:
- No clear explanation why ticagrelor worse in North America.8
- Dyspnea unexplained3 but is not associated with structural cardiac damage or pulmonary function test abnormalities.9,10
- Ticagrelor is significantly more expensive than clopidogrel ($310/90 days vs. $100/90 days)11 and requires twice-daily dosing.
- Given the cost, increased harms, and uncertainty around effectiveness in North America, clinicians should:
- Consider clopidogrel a reasonable alternative in intolerant patients started on ticagrelor in hospital.
Latest Tools for Practice
#348 How to Slow the Flow III: Tranexamic acid for heavy menstrual bleeding (Free)
In premenopausal heavy menstrual bleeding due to benign etiology, does tranexamic acid (TXA) improve patient outcomes?
#347 Chlorthali-D’OH!: What is the best thiazide diuretic for hypertension?
Which thiazide diuretic is best at reducing cardiovascular events in hypertension?
#346 Stress Urinary Incontinence: Pelvic floor exercises or pessary? (Free)
How effective are pelvic floor exercises or pessaries for stress urinary incontinence?
